AI Article Synopsis

  • - Tissue engineering is advancing the creation of artificial human cardiac muscle patches (hCMPs) to help treat Myocardial infarction (MI) by enhancing heart regeneration.
  • - Challenges such as low engraftment rates, scalability issues for clinical use, and the need for a functional vascular system hinder hCMP's practical implementation.
  • - The paper explores various heart cell types for hCMP production, innovative engineering methods, and the significance of cell injection/transplantation in cardiac tissue engineering.

Article Abstract

Tissue engineering has paved the way for the development of artificial human cardiac muscle patches (hCMPs) and cardiac tissue analogs, especially for treating Myocardial infarction (MI), often by increasing its regenerative abilities. Low engraftment rates, insufficient clinical application scalability, and the creation of a functional vascular system remain obstacles to hCMP implementation in clinical settings. This paper will address some of these challenges, present a broad variety of heart cell types and sources that can be applied to hCMP biomanufacturing, and describe some new innovative methods for engineering such treatments. It is also important to note the injection/transplantation of cells in cardiac tissue engineering.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687338PMC
http://dx.doi.org/10.3390/bioengineering9110696DOI Listing

Publication Analysis

Top Keywords

cardiac tissue
12
tissue engineering
12
advances cardiac
4
tissue
4
engineering
4
engineering tissue
4
engineering paved
4
paved development
4
development artificial
4
artificial human
4

Similar Publications

Avian Reovirus: From Molecular Biology to Pathogenesis and Control.

Viruses

December 2024

Southeast Poultry Research Laboratory, U.S. National Poultry Research Center, United States Department of Agriculture-Agricultural Research Service (USDA-ARS), Athens, GA 30605, USA.

Avian reoviruses (ARVs) represent a significant economic burden on the poultry industry due to their widespread prevalence and potential pathogenicity. These viruses, capable of infecting a diverse range of avian species, can lead to a variety of clinical manifestations, most notably tenosynovitis/arthritis. While many ARV strains are asymptomatic, pathogenic variants can cause severe inflammation and tissue damage in organs such as the tendons, heart, and liver.

View Article and Find Full Text PDF

Dietary sulfur amino acid restriction (SAAR) elicits various health benefits, some mediated by fibroblast growth factor 21 (FGF21). However, research on SAAR's effects on the heart is limited and presents mixed findings. This study aimed to evaluate SAAR-induced molecular alterations associated with cardiac remodeling and their dependence on FGF21.

View Article and Find Full Text PDF

The Chansu injection (CSI), a sterile aqueous solution derived from Chansu, is applied in clinical settings to support antitumor and anti-radiation treatments. CSI's principal active components, bufadienolides (≥90%), demonstrate potential effects on pancreatic cancer (PDAC), but their underlying mechanisms remain unclear. This study aimed to elucidate the antitumor effects and pathways associated with CSI in PDAC.

View Article and Find Full Text PDF

Iodine-123 metaiodobenzylguanidine (I-123 MIBG) is a crucial radiopharmaceutical widely used in nuclear medicine for its diagnostic capabilities in both cardiology and oncology. This review aims to present a comprehensive evaluation of the clinical applications of I-123 MIBG, focusing on its use in diagnosing and managing various diseases. In cardiology, I-123 MIBG has proven invaluable in assessing cardiac sympathetic innervation, particularly in patients with heart failure, where it provides prognostic information that guides treatment strategies.

View Article and Find Full Text PDF

Ninoa Strain Modifies the Expression of microRNAs in Cardiac Tissue and Plasma During Chagas Disease Infection.

Pathogens

December 2024

Departamento de Inmunología, Instituto Nacional de Cardiología Ignacio Chávez (INCICH), Mexico City 14080, Mexico.

Chronic chagasic cardiomyopathy is the most severe clinical manifestation of Chagas disease, which affects approximately seven million people worldwide. Latin American countries bear the highest burden, with the greatest morbidity and mortality rates. Currently, diagnostic methods do not provide information on the risk of progression to severe stages of the disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!